Incyte has initiated a Phase I clinical trial of INCB13739, an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears
to be critical to the development of Type 2 diabetes.
The trial is a
double-blind, placebo-controlled, single- and multiple-dose-rising study designed
to assess the safety and pharmacokinetics of INCB13739 in healthy volunteers.
The program will also evaluate the ability of INCB13739 to inhibit 11beta-HSD1
activity in adipose tissue and liver of high-body mass index individuals. Preclinical
studies have shown that 11beta-HSD1 activity in these two tissues may be a primary
driver of insulin resistance and diabetes.
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
CoreLink’s 3D Anterior Lumbar Approved by FDA
The implant allows for better imaging by minimizing material density.
Endo Resumes Lawsuit Against FDA Over Bulk Drug Compounding Decree
The company claimed the agency’s handling of bulk compounding laws violates the 2013 Drug Quality and Security Act, treating the laws as non-binding guidance rather than a legal mandate.